Icon: enlarge
Vaccines: Billionaire Business Pandemic
Photo: Luka Dakskobler / dpa
Vaccine maker Moderna expects sales of more than $ 18 billion in 2021.
The US company announced this when it presented its quarterly balance sheet.
In the past year, research and development costs had resulted in high losses for the company: In the three months to the end of December, Moderna lost a total of $ 272.5 million.
The losses were already compared to a multiple turnover in 2020: In the last quarter, Moderna had sales of $ 570.7 million, previously it had been 14.1 million.
The ongoing vaccination campaigns should give the company a further boost.
Moderna's corona vaccine is in great demand, global demand far exceeds supply.
In 2021, plans are being made to increase vaccine production capacities to 1.4 billion vaccine doses, said Moderna's CEO Stéphane Bancel.
Moderna manufactures one of two mRNA vaccines approved in Europe.
The other vaccine comes from Biontech and Pfizer.
Biontech and Pfizer are forecasting sales of around $ 15 billion for the vaccine they have developed in 2021.
Moderna was founded in 2010.
It went public at the end of 2018.
The company's stock had risen more than 450 percent in the past twelve months due to the vaccine boom.
So far, however, the company has not been in the black: In 2020, a total of $ 747.1 million was down.
Icon: The mirror
jlk / dpa
